The DOI matches its Crossref record.
Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy
Abstract
Objectives: 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)–linked iron oxide nanoparticle (bioprobes) pharmacokinetics, tumor uptake, and the therapeutic effect of inductively heating these bioprobes by externally applied alternating magnetic field (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. Tumor cell radioimmunotargeting of the bioprobes and therapeutic and toxic responses were determined. Methods: Using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HCl, 111In-7,10-tetra-azacyclododecane-N, N′,N″,N‴-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20 nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 ng/2.2 mg ChL6/ bioprobe), i.v. with 50 μg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of 111In-ChL6. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown with up to eight times longer mean time to quintuple tumor volume with therapy compared with no treatment (P = 0.0013). Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths and skin erythema. Electron micrographs showed bioprobes on the surfaces of the HBT 3477 cells of excised tumors and tumor necrosis 24 hours after AMF/bioprobe therapy. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen, so that bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Reddy, L. H., Arias, J. L., Nicolas, J., & Couvreur, P. (2012) · Chemical Reviews · doi:10.1021/cr300068p · Cited by 2,010
Progress in applications of magnetic nanoparticles in biomedicine
Pankhurst, Q. A., Thanh, N. T. K., Jones, S. K., & Dobson, J. (2009) · Journal of Physics D: Applied Physics · doi:10.1088/0022-3727/42/22/224001 · Cited by 1,455
Biological applications of magnetic nanoparticles
Colombo, M., Carregal-Romero, S., Casula, M. F., Gutiérrez, L., Morales, M. P., Böhm, I. B., Heverhagen, J. T., Prosperi, D., & Parak, W. J. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15337h · Cited by 1,315
A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications
James, M. L., & Gambhir, S. S. (2012) · Physiological Reviews · doi:10.1152/physrev.00049.2010 · Cited by 1,140
Metadata
- Authors
- DeNardo, S. J., DeNardo, G. L., Miers, L. A., Natarajan, A., Foreman, A. R., Gruettner, C., Adamson, G. N., & Ivkov, R.
- Venue
- Clinical Cancer Research
- Published
- 2005-10-01
- Volume
- 11
- Issue
- 19
- Pages
- 7087s-7092s
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2114107793
- Cited by
- 200
- References
- 0
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-1004-0022
- The paper
- DeNardo, S. J., DeNardo, G. L., Miers, L. A., Natarajan, A., Foreman, A. R., Gruettner, C., Adamson, G. N., & Ivkov, R. (2005). Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-1004-0022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.